DOSEGUY

SR-9011

guinea pig

Also seen as: SR9011, SR 9011, sr

The Dose Guy’s verdict
Sep 1, 2026
2 sources

Skip it. SR-9011 is the less-studied twin, same REV-ERB mechanism as SR-9009, same absorption problem, a fraction of the already-thin evidence. SR-9011 exists in the literature mostly as a co-star in cancer and inflammation cell studies that have nothing to do with fat loss or endurance. If you want pharmacological help with weight, retatrutide or tirzepatide are the shelf to look at.

Would I take it?Skip. Even less behind it than the twin.

What it is

SR-9009’s structural twin from the same lab, another REV-ERB agonist built to modulate the circadian clock machinery that regulates metabolism, fat storage, and inflammation in rodent models. The pitch is identical. The literature is not: SR-9011 appears almost exclusively in oncology and immunology cell work. The papers cover breast cancer lines, glioblastoma, microglia, and lung fibroblasts, not the exercise or weight-loss claims that drive supplement sales.

Everything that undermines SR-9009 applies here. The REV-ERB independence findings were done with SR-9009, but the compounds share enough structural ground that the same question hangs over both. The oral bioavailability problem looks the same: human liver microsomal assays turned up 14 SR-9011 metabolites, which tells you the liver chews through it aggressively.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Almost entirely cell work. The animal data that exists comes from papers where SR-9011 co-stars alongside SR-9009, not from studies of SR-9011 on its own terms.

SR-9009 and SR-9011 were lethal to cancer and oncogene-induced senescent cells while showing no effect on the viability of normal cells or tissues.Nature 2018 · cells + mice
In human lung fibroblasts, REV-ERB agonists including SR-9011 inhibited TGF-beta-1-induced fibroblast-to-myofibroblast transition and reduced IL-6 release.BBRC 2023 · human lung fibroblasts
No human intervention trial evaluating SR-9011 exists.as of Aug 2026

Realistic protocols

I am not building a protocol for SR-9011. The community runs it interchangeably with SR-9009, same 20 to 30 mg oral range, same split dosing, same bioavailability problem. There is no study, human or animal, that tells you SR-9011 is better, worse, or meaningfully different from SR-9009 for anything you are trying to do. If you run it anyway: source with a COA, go low, keep runs short, log everything, and get bloodwork before and after.

Side effects

No human safety data. The risk profile is borrowed from the SR-9009 story and cell-line work:

anecdotalSame forum reports as SR-9009: disrupted sleep, mild GI complaints. The compounds are used interchangeably, so the anecdotes blend together.
unknownThe REV-ERB independence question that hangs over SR-9009 hangs here too. You do not know the actual mechanism you are engaging, and there is zero human safety data to backstop you.

Where to buy

No live listings from tracked vendors right now.